Article
[Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation].
Gan to kagaku ryoho. Cancer & chemotherapy - 1 Sept 2017
Hayashi Hidetoshi, Mitsudomi Tetsuya
Abstract excerpt
Recent clinical evidence that anti-PD-1/PD-L1 antibody therapy is superior to cytotoxic chemotherapy for patients with non-small cell lung cancer(NSCLC)that expresses PD-L1 has lead to a paradigm shift in treatment strategies for those patients. However, efficacy of anti-PD-1/PD-L1 antibodies for patients with NSCLC harboring EGFR mutation is generally poor. This lack ofresponse is at least partially attributed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.